Alogliptin vs Trelagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Alogliptin · Nesina
Marketed by Takeda Pharmaceutical Company and partners
NCT00286429 · Phase 3 · completed
The 390-participant trial was randomized, quadruple-blind, and placebo-controlled, with 130, 131, and 129 participants assigned to placebo, alogliptin 12.5 mg, and alogliptin 25 mg, respectively. Both primary HbA1c comparisons were statistically significant in favor of alogliptin, but HbA1c is a surrogate measure, so the evidence does not establish a strong clinical-outcome grade.
Next expected readout: December 2026 · NCT07093476 (registry estimate)
Reported efficacy
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) (missed)
Result source: NCT02856113
Trelagliptin · Zafatek
Marketed by Teijin and partners
NCT01431807 · Phase 3 · completed
This was a single-group, open-label study with no randomization, blinding, or comparator arm, despite enrolling 680 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT07073768 (registry estimate)
Reported efficacy
Change From Baseline in HbA1c at the End of Treatment Period I (Baseline (Week 0) and end of Treatment Period I (Up to Week 12)); Number of Participants Who Had One or More Treatment Emergent Adverse Event (TEAE) Before the Start of Study Drug Administration in Treatment Period II (Up to Week 12); Number of Participants Who Had One or More TEAE Occurred After 1st Dose of Trelagliptin 25 mg Tablet (Up to Week 54): Change From Baseline in HbA1c at the End of Treatment Period I (Baseline (Week 0) and end of Treatment Period I (Up to Week 12)): Trelagliptin 25 mg -0.71 Percent HbA1c (Standard Error 0.087) vs Placebo and Trelagliptin 25 mg 0.01 Percent HbA1c (Standard Error 0.089) (met)
Result source: NCT02512068
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Alogliptin | Trelagliptin |
|---|---|---|
| HbA1c, change | -0.7% vs -0.1%−0.6 vs placeboNCT00286429285 other results
| -0.7% vs 0.0%−0.7 vs placeboNCT025120684 other results
|
| Body weight, change (kg) | 0.6 vs 0.6±0 vs placeboNCT00286429111 other results
| —Not posted · NCT03940183 |
| HbA1c below 7% | 63.3% vs 30%+33.3 vs placeboNCT012891192 other results
| —Not posted · NCT03940183 |
| Fasting plasma glucose, change | -0.2 vs -0.1−0.1 vs placeboNCT00286429351 other results
| -0.9 vs -0.0−0.9 vs placeboNCT025120683 other results
|
| 3-point MACE (% with event) | 11.3% vs 11.8%−0.5 vs placeboNCT00968708 | —Not posted · NCT03940183 |
HbA1c, change
- Alogliptin
- -0.7% vs -0.1%−0.6 vs placeboNCT00286429
285 other results
- -0.6% vs -0.0% NCT00286455
- 0.1% vs -0.0% NCT02856113
- -0.5% vs 0.1% NCT01023581
- -0.9% vs -0.1% NCT00328627
- -0.8% vs -0.2% NCT00286494
- -0.6% vs -0.1% NCT00286442
- -0.6% vs -0.1% NCT00286429
- -0.6% vs -0.0% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.6% vs -0.1% NCT00328627
- -0.7% vs -0.2% NCT00286494
- -0.6% vs -0.1% NCT00286442
- -1.3% vs -0.1% NCT00328627
- -1.4% vs -0.1% NCT00328627
- -1.6% vs -0.1% NCT00328627
- -1.2% vs 0.1% NCT01023581
- -1.6% vs 0.1% NCT01023581
- -1.3% vs -0.1% NCT00328627
- -1.4% vs -0.1% NCT00328627
- -1.6% vs -0.1% NCT00328627
- -1.0% vs -0.4% NCT01289119
- -0.9% vs -0.4% NCT01289119
- -0.8% vs -0.4% NCT01289119
- -1.0% vs -1.1% NCT00395512
- -1.0% vs 0.0% NCT01263483
- -0.7% vs 0.3% NCT01318083
- -1.0% vs -0.2% NCT01318070
- -0.9% vs -0.4% NCT00432276
- -0.9% vs 0.0% NCT01263483
- -1.7% vs -1.1% NCT00395512
- -0.8% vs -0.7% NCT00856284
- -0.7% vs -0.3% NCT00432276
- -0.7% vs -0.6% NCT00856284
- -0.6% vs 0.3% NCT01318083
- -0.9% vs -0.2% NCT01318070
- -1.6% vs -1.1% NCT00395512
- -0.8% vs -0.7% NCT00856284
- -0.7% vs -0.6% NCT00856284
- -0.8% vs -0.3% NCT00286429
- -0.7% vs -0.1% NCT00286455
- -0.4% vs -0.3% NCT02856113
- -0.5% vs 0.1% NCT01023581
- -0.9% vs -0.3% NCT00328627
- -0.8% vs -0.2% NCT00286494
- -0.7% vs -0.2% NCT00286442
- -0.8% vs -0.3% NCT00286429
- -0.8% vs -0.2% NCT00286429
- -0.6% vs -0.1% NCT00286455
- -0.7% vs -0.1% NCT00286455
- -0.5% vs 0.1% NCT01023581
- -0.6% vs 0.1% NCT01023581
- -0.8% vs -0.3% NCT00328627
- -1.0% vs -0.3% NCT00328627
- -0.7% vs -0.2% NCT00286494
- -0.8% vs -0.3% NCT00286494
- -0.6% vs -0.2% NCT00286442
- -0.6% vs -0.1% NCT00286442
- -0.2% vs -0.2% NCT02856113
- -0.6% vs -0.3% NCT00286429
- -0.7% vs -0.2% NCT00286429
- -0.5% vs -0.1% NCT00286455
- -0.6% vs -0.1% NCT00286455
- -0.3% vs 0.1% NCT01023581
- -0.6% vs 0.1% NCT01023581
- -0.5% vs -0.2% NCT00328627
- -1.0% vs -0.2% NCT00328627
- -0.5% vs -0.1% NCT00286494
- -0.8% vs -0.3% NCT00286494
- -0.4% vs -0.1% NCT00286442
- -0.6% vs -0.1% NCT00286442
- 0.1% vs 0.5% NCT02856113
- 0.3% vs 0.8% NCT02856113
- -0.8% vs -0.3% NCT00286429
- -0.6% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.8% vs -0.3% NCT00328627
- -0.7% vs -0.2% NCT00286494
- -0.7% vs -0.2% NCT00286442
- -0.8% vs -0.3% NCT00286429
- -0.8% vs -0.2% NCT00286429
- -0.5% vs -0.1% NCT00286455
- -0.6% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.6% vs 0.1% NCT01023581
- -0.8% vs -0.3% NCT00328627
- -0.8% vs -0.3% NCT00328627
- -0.6% vs -0.2% NCT00286494
- -0.7% vs -0.3% NCT00286494
- -0.6% vs -0.2% NCT00286442
- -0.7% vs -0.1% NCT00286442
- -0.5% vs -0.3% NCT00286429
- -0.8% vs -0.2% NCT00286429
- -0.4% vs -0.1% NCT00286455
- -0.6% vs -0.1% NCT00286455
- -0.4% vs 0.1% NCT01023581
- -0.6% vs 0.1% NCT01023581
- -0.5% vs -0.2% NCT00328627
- -0.8% vs -0.2% NCT00328627
- -0.4% vs -0.1% NCT00286494
- -0.7% vs -0.3% NCT00286494
- -0.4% vs -0.1% NCT00286442
- -0.6% vs -0.1% NCT00286442
- -1.3% vs -0.3% NCT00328627
- -1.3% vs -0.3% NCT00328627
- -1.5% vs -0.3% NCT00328627
- -1.0% vs -0.3% NCT00328627
- -1.0% vs -0.3% NCT00328627
- -1.2% vs -0.3% NCT00328627
- -1.4% vs -0.3% NCT00328627
- -1.4% vs -0.3% NCT00328627
- -1.7% vs -0.3% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -1.4% vs -0.2% NCT00328627
- -1.5% vs -0.2% NCT00328627
- -1.7% vs -0.2% NCT00328627
- -1.2% vs 0.1% NCT01023581
- -1.4% vs 0.1% NCT01023581
- -1.2% vs -0.3% NCT00328627
- -1.3% vs -0.3% NCT00328627
- -1.3% vs -0.3% NCT00328627
- -1.1% vs 0.1% NCT01023581
- -1.2% vs 0.1% NCT01023581
- -1.3% vs 0.1% NCT01023581
- -1.5% vs 0.1% NCT01023581
- -1.0% vs -0.3% NCT00328627
- -1.1% vs -0.3% NCT00328627
- -1.1% vs -0.3% NCT00328627
- -1.4% vs -0.3% NCT00328627
- -1.4% vs -0.3% NCT00328627
- -1.5% vs -0.3% NCT00328627
- -0.7% vs 0.1% NCT01023581
- -0.8% vs 0.1% NCT01023581
- -1.3% vs 0.1% NCT01023581
- -1.5% vs 0.1% NCT01023581
- -0.5% vs -0.2% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -1.4% vs -0.2% NCT00328627
- -1.4% vs -0.2% NCT00328627
- -1.6% vs -0.2% NCT00328627
- -1.0% vs -0.4% NCT01289119
- -0.9% vs -0.4% NCT01289119
- -0.8% vs -0.4% NCT01289119
- -0.9% vs -0.4% NCT01289119
- -0.7% vs -0.4% NCT01289119
- -0.7% vs -0.4% NCT01289119
- -0.6% vs -0.2% NCT01289119
- -0.4% vs -0.2% NCT01289119
- -0.4% vs -0.2% NCT01289119
- -1.0% vs -1.0% NCT00395512
- -0.8% vs -0.7% NCT00395512
- -1.0% vs -1.2% NCT00395512
- -0.6% vs -0.3% NCT00395512
- -1% vs -1.2% NCT00395512
- -0.7% vs -0.8% NCT00856284
- -0.8% vs -0.3% NCT00432276
- -0.6% vs -0.7% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.7% vs -0.3% NCT00432276
- -0.9% vs -0.4% NCT00432276
- -0.4% vs -0.4% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.4% vs -0.1% NCT00432276
- -0.9% vs -0.5% NCT00432276
- -0.8% vs -0.8% NCT00856284
- -0.8% vs -0.4% NCT00432276
- -0.8% vs -0.7% NCT00856284
- -0.8% vs -0.4% NCT00432276
- -0.8% vs -0.8% NCT00856284
- -0.8% vs -0.7% NCT00856284
- -0.8% vs -0.7% NCT00856284
- -0.7% vs -0.8% NCT00856284
- -0.6% vs -0.7% NCT00856284
- -0.7% vs -0.8% NCT00856284
- -0.4% vs -0.4% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.8% vs -0.7% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.8% vs -0.7% NCT00856284
- -0.8% vs -0.7% NCT00856284
- -0.7% vs -0.0% NCT01263483
- -0.4% vs -0.0% NCT01263483
- -0.2% vs -0.0% NCT01263483
- -1.6% vs -1.0% NCT00395512
- -1.2% vs -0.7% NCT00395512
- -1.7% vs -1.2% NCT00395512
- -0.6% vs 0.2% NCT01318083
- -0.8% vs -0.2% NCT01318070
- -0.8% vs -0.0% NCT01263483
- -0.6% vs -0.3% NCT00395512
- -1.7% vs -1.2% NCT00395512
- -0.4% vs 0.1% NCT01318083
- -0.5% vs -0.1% NCT01318070
- -0.4% vs -0.0% NCT01263483
- -0.1% vs 0.1% NCT01318083
- -0.2% vs -0.0% NCT01318070
- -0.2% vs -0.0% NCT01263483
- -1.3% vs -1.0% NCT00395512
- -1.0% vs -0.7% NCT00395512
- -1.4% vs -1.2% NCT00395512
- -0.5% vs 0.2% NCT01318083
- -0.8% vs -0.2% NCT01318070
- -0.5% vs -0.3% NCT00395512
- -1.5% vs -1.2% NCT00395512
- -0.3% vs 0.1% NCT01318083
- -0.5% vs -0.1% NCT01318070
- -0.1% vs 0.1% NCT01318083
- -0.2% vs -0.0% NCT01318070
- -0.8% vs 0.1% NCT01263470
- -0.6% vs -0.0% NCT00755846
- -0.7% vs 0.1% NCT01263470
- -0.5% vs -0.0% NCT00755846
- -0.5% vs -0.0% NCT00755846
- -0.8% vs 0.1% NCT01263470
- -0.4% vs -0.0% NCT00755846
- -0.5% vs 0.1% NCT01263470
- -0.2% vs -0.0% NCT00755846
- -0.7% vs 0% NCT01263470
- -0.4% vs 0.0% NCT00755846
- -0.3% vs -0.0% NCT01263470
- -0.2% vs 0% NCT01263470
- -0.6% vs 0% NCT01263470
- -0.3% vs 0.0% NCT00755846
- -0.4% vs -0.0% NCT01263470
- -0.2% vs 0% NCT01263470
- -0.3% vs 0.0% NCT00755846
- -0.7% vs 0% NCT01263470
- -0.3% vs 0.0% NCT00755846
- -0.4% vs -0.0% NCT01263470
- -0.1% vs 0% NCT01263470
- -0.5% vs 0% NCT01263470
- -0.1% vs 0.0% NCT00755846
- -0.3% vs -0.0% NCT01263470
- -0.2% vs 0% NCT01263470
- -0.7% vs -0.1% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.8% vs -0.4% NCT01263496
- -0.7% vs -0.4% NCT01263496
- -0.6% vs -0.2% NCT01263496
- -0.7% vs -0.1% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.5% vs -0.3% NCT01263496
- -0.5% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.7% vs -0.4% NCT01263496
- -0.7% vs -0.4% NCT01263496
- -0.5% vs -0.2% NCT01263496
- -0.9% vs -0.1% NCT01263496
- -0.9% vs -0.3% NCT01263496
- -0.9% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.4% NCT01263496
- -0.8% vs -0.4% NCT01263496
- -0.9% vs -0.2% NCT01263496
- -0.6% vs -0.1% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.5% vs -0.3% NCT01263496
- -0.4% vs -0.3% NCT01263496
- -0.3% vs -0.3% NCT01263496
- -0.3% vs -0.3% NCT01263496
- -0.3% vs -0.3% NCT01263496
- -0.3% vs -0.3% NCT01263496
- -0.4% vs -0.4% NCT01263496
- -0.5% vs -0.4% NCT01263496
- -0.4% vs -0.2% NCT01263496
- Trelagliptin
- -0.7% vs 0.0%−0.7 vs placeboNCT02512068
4 other results
- -0.7% vs 0.0% NCT02512068
- -0.6% vs -0.1% NCT02512068
- -0.5% vs 0.0% NCT02512068
- -0.2% vs 0.1% NCT02512068
Body weight, change (kg)
- Alogliptin
- 0.6 vs 0.6±0 vs placeboNCT00286429
111 other results
- -0.2 vs 0.2 NCT00286455
- -0.7 vs -0.7 NCT00328627
- 1.1 vs 1.0 NCT00286494
- -0.7 vs -0.4 NCT00286442
- 0.7 vs -0.2 NCT00286468
- 0.5 vs 0.7 NCT00286429
- -0.2 vs -0.2 NCT00286455
- -0.5 vs -0.6 NCT00328627
- 0.9 vs 0.9 NCT00286494
- -0.6 vs -0.4 NCT00286442
- 0.6 vs -0.3 NCT00286468
- 0.3 vs 0.5 NCT00286429
- 0.1 vs -0.3 NCT00286455
- -0.6 vs -0.5 NCT00328627
- 0.6 vs 0.6 NCT00286494
- -0.6 vs -0.6 NCT00286442
- 0.4 vs -0.1 NCT00286468
- 0.2 vs 0.4 NCT00286429
- -0.0 vs -0.4 NCT00286455
- -0.5 vs -0.1 NCT00328627
- 0.4 vs 0.4 NCT00286494
- -0.5 vs -0.1 NCT00286442
- 0.3 vs -0.3 NCT00286468
- 0.7 vs 0.6 NCT00286429
- -0.1 vs 0.2 NCT00286455
- -0.0 vs -0.7 NCT00328627
- 1.5 vs 1.0 NCT00286494
- -0.4 vs -0.4 NCT00286442
- 0.6 vs -0.2 NCT00286468
- 0.6 vs 0.7 NCT00286429
- -0.2 vs -0.2 NCT00286455
- -0.1 vs -0.6 NCT00328627
- 1.1 vs 0.9 NCT00286494
- -0.4 vs -0.4 NCT00286442
- 0.8 vs -0.3 NCT00286468
- 0.4 vs 0.5 NCT00286429
- -0.4 vs -0.3 NCT00286455
- -0.1 vs -0.5 NCT00328627
- 0.7 vs 0.6 NCT00286494
- -0.3 vs -0.6 NCT00286442
- 0.6 vs -0.1 NCT00286468
- 0.1 vs 0.4 NCT00286429
- 0.0 vs -0.4 NCT00286455
- -0.1 vs -0.1 NCT00328627
- 0.5 vs 0.4 NCT00286494
- -0.3 vs -0.1 NCT00286442
- 0.5 vs -0.3 NCT00286468
- 1.3 vs -0.7 NCT00328627
- 2.1 vs -0.7 NCT00328627
- 2.3 vs -0.7 NCT00328627
- 0.8 vs -0.6 NCT00328627
- 1.8 vs -0.6 NCT00328627
- 1.8 vs -0.6 NCT00328627
- 0.4 vs -0.5 NCT00328627
- 1.0 vs -0.5 NCT00328627
- 1.1 vs -0.5 NCT00328627
- 0.2 vs -0.1 NCT00328627
- 0.7 vs -0.1 NCT00328627
- 0.9 vs -0.1 NCT00328627
- 1.3 vs -0.7 NCT00328627
- 1.9 vs -0.7 NCT00328627
- 2.3 vs -0.7 NCT00328627
- 1.0 vs -0.6 NCT00328627
- 1.4 vs -0.6 NCT00328627
- 1.9 vs -0.6 NCT00328627
- 0.2 vs -0.5 NCT00328627
- 0.6 vs -0.5 NCT00328627
- 0.9 vs -0.5 NCT00328627
- 0.1 vs -0.1 NCT00328627
- 0.5 vs -0.1 NCT00328627
- 0.4 vs -0.1 NCT00328627
- -0.9 vs -1.6 NCT01289119
- -0.8 vs -1.6 NCT01289119
- -0.1 vs -1.6 NCT01289119
- -0.7 vs -1.0 NCT01289119
- -0.4 vs -1.0 NCT01289119
- -0.1 vs -1.0 NCT01289119
- -0.9 vs 0.9 NCT00856284
- -0.9 vs 0.9 NCT00856284
- -0.9 vs 0.9 NCT00856284
- -0.9 vs 0.9 NCT00856284
- -0.9 vs 0.9 NCT00856284
- 1.1 vs 1.6 NCT00432276
- 1.1 vs 1.5 NCT00432276
- -0.9 vs 1.0 NCT00856284
- -0.7 vs 0.9 NCT00856284
- 0.7 vs 1.0 NCT00432276
- -0.5 vs 0.7 NCT00856284
- 0.3 vs 0.6 NCT00432276
- 0.3 vs 0.5 NCT00432276
- 0.2 vs 0.3 NCT00432276
- -0.7 vs 0.9 NCT00856284
- -0.7 vs 0.9 NCT00856284
- -0.8 vs 0.9 NCT00856284
- -0.7 vs 0.9 NCT00856284
- -0.6 vs 0.9 NCT00856284
- -0.6 vs 1.0 NCT00856284
- -0.7 vs 0.9 NCT00856284
- -0.5 vs 0.7 NCT00856284
- -0.3 vs 2.2 NCT00395512
- -0.5 vs 1.6 NCT00395512
- -0.8 vs 1.0 NCT00395512
- -0.3 vs 0.6 NCT00395512
- 3.1 vs 2.2 NCT00395512
- 2.4 vs 1.6 NCT00395512
- 1.4 vs 1.0 NCT00395512
- 0.8 vs 0.6 NCT00395512
- 2.5 vs 2.2 NCT00395512
- 1.9 vs 1.6 NCT00395512
- 1.2 vs 1.0 NCT00395512
- 0.7 vs 0.6 NCT00395512
- Trelagliptin
- —Not posted · NCT03940183
HbA1c below 7%
- Alogliptin
- 63.3% vs 30%+33.3 vs placeboNCT01289119
2 other results
- 55.1% vs 30% NCT01289119
- 61.7% vs 30% NCT01289119
- Trelagliptin
- —Not posted · NCT03940183
Fasting plasma glucose, change
- Alogliptin
- -0.2 vs -0.1−0.1 vs placeboNCT00286429
351 other results
- -1.1 vs 0.1 NCT00286455
- -0.5 vs 0.6 NCT01023581
- -1.3 vs 0.2 NCT00328627
- -1.4 vs -0.6 NCT00286494
- -0.9 vs 0.0 NCT00286442
- -0.8 vs -0.2 NCT00286468
- -0.8 vs 0.3 NCT00286429
- -0.3 vs 0.3 NCT00286429
- -1.1 vs 0.1 NCT00286455
- -1.0 vs 0.3 NCT00286455
- -0.6 vs 0.4 NCT01023581
- -0.4 vs 0.6 NCT01023581
- -1.1 vs 0.3 NCT00328627
- -1.3 vs 0.1 NCT00328627
- -1.5 vs -0.3 NCT00286494
- -1.3 vs -0.5 NCT00286494
- -0.9 vs 0.0 NCT00286442
- -0.8 vs 0.1 NCT00286442
- -1.0 vs -0.2 NCT00286468
- -0.7 vs -0.4 NCT00286468
- -0.7 vs 0.3 NCT00286429
- -0.6 vs 0.5 NCT00286429
- -1.2 vs 0.2 NCT00286455
- -1.0 vs 0.4 NCT00286455
- -0.6 vs 0.4 NCT01023581
- -0.5 vs 0.5 NCT01023581
- -1.3 vs 0.2 NCT00328627
- -1.3 vs 0.4 NCT00328627
- -1.4 vs -0.2 NCT00286494
- -1.2 vs -0.4 NCT00286494
- -1 vs -0.0 NCT00286442
- -0.9 vs -0.0 NCT00286442
- -1.2 vs -0.2 NCT00286468
- -0.8 vs -0.0 NCT00286468
- -0.6 vs 0.1 NCT00286429
- -1.0 vs 0.2 NCT00286455
- -0.4 vs 0.3 NCT01023581
- -1.1 vs 0.3 NCT00328627
- -1.2 vs -0.1 NCT00286494
- -1.0 vs -0.0 NCT00286442
- -1.2 vs -0.1 NCT00286468
- -0.6 vs 0.3 NCT00286429
- -0.8 vs 0.3 NCT00286455
- -0.2 vs 0.3 NCT01023581
- -1.0 vs 0.1 NCT00328627
- -1.0 vs -0.1 NCT00286494
- -0.7 vs -0.0 NCT00286442
- -1.1 vs 0.0 NCT00286468
- -0.7 vs 0.3 NCT00286429
- -0.9 vs 0.6 NCT00286455
- -0.3 vs 0.7 NCT01023581
- -1.0 vs 0.4 NCT00328627
- -1.1 vs -0.3 NCT00286494
- -1.0 vs 0 NCT00286442
- -0.5 vs 0.1 NCT00286468
- -0.3 vs -0.1 NCT00286429
- -0.8 vs 0.1 NCT00286455
- -0.8 vs 0.6 NCT01023581
- -1.1 vs 0.2 NCT00328627
- -1.1 vs -0.6 NCT00286494
- -0.9 vs 0.0 NCT00286442
- -0.8 vs -0.2 NCT00286468
- -0.8 vs 0.3 NCT00286429
- -0.3 vs 0.3 NCT00286429
- -0.8 vs 0.1 NCT00286455
- -0.8 vs 0.3 NCT00286455
- -0.7 vs 0.4 NCT01023581
- -0.8 vs 0.6 NCT01023581
- -1.1 vs 0.3 NCT00328627
- -0.9 vs 0.1 NCT00328627
- -1.3 vs -0.3 NCT00286494
- -1.0 vs -0.5 NCT00286494
- -1.1 vs 0.0 NCT00286442
- -1.0 vs 0.1 NCT00286442
- -1.1 vs -0.2 NCT00286468
- -0.5 vs -0.4 NCT00286468
- -0.3 vs 0.3 NCT00286429
- -0.2 vs 0.5 NCT00286429
- -0.9 vs 0.2 NCT00286455
- -0.7 vs 0.4 NCT00286455
- -0.9 vs 0.4 NCT01023581
- -0.7 vs 0.5 NCT01023581
- -1.1 vs 0.2 NCT00328627
- -0.5 vs 0.4 NCT00328627
- -1.3 vs -0.2 NCT00286494
- -1.2 vs -0.4 NCT00286494
- -1.0 vs -0.0 NCT00286442
- -1 vs -0.0 NCT00286442
- -0.8 vs -0.2 NCT00286468
- -0.5 vs -0.0 NCT00286468
- -0.2 vs 0.1 NCT00286429
- -0.8 vs 0.2 NCT00286455
- -0.6 vs 0.3 NCT01023581
- -1.2 vs 0.3 NCT00328627
- -1.2 vs -0.1 NCT00286494
- -1.0 vs -0.0 NCT00286442
- -0.9 vs -0.1 NCT00286468
- -0.3 vs 0.3 NCT00286429
- -0.5 vs 0.3 NCT00286455
- -0.7 vs 0.3 NCT01023581
- -0.8 vs 0.1 NCT00328627
- -0.8 vs -0.1 NCT00286494
- -0.8 vs -0.0 NCT00286442
- -0.7 vs 0.0 NCT00286468
- 0.1 vs 0.3 NCT00286429
- -0.6 vs 0.6 NCT00286455
- -0.5 vs 0.7 NCT01023581
- -0.7 vs 0.4 NCT00328627
- -1.1 vs -0.3 NCT00286494
- -1.0 vs 0 NCT00286442
- -0.3 vs 0.1 NCT00286468
- -2.4 vs 0.2 NCT00328627
- -2.7 vs 0.2 NCT00328627
- -2.9 vs 0.2 NCT00328627
- -2.2 vs 0.3 NCT00328627
- -2.5 vs 0.3 NCT00328627
- -2.9 vs 0.3 NCT00328627
- -2.2 vs 0.1 NCT00328627
- -2.4 vs 0.1 NCT00328627
- -3.0 vs 0.1 NCT00328627
- -2.1 vs 0.2 NCT00328627
- -2 vs 0.2 NCT00328627
- -2.6 vs 0.2 NCT00328627
- -2.2 vs 0.4 NCT00328627
- -2.4 vs 0.4 NCT00328627
- -2.9 vs 0.4 NCT00328627
- -1.8 vs 0.3 NCT00328627
- -1.7 vs 0.3 NCT00328627
- -1.8 vs 0.3 NCT00328627
- -1.2 vs 0.1 NCT00328627
- -1.3 vs 0.1 NCT00328627
- -1.4 vs 0.1 NCT00328627
- -2.1 vs 0.4 NCT00328627
- -2.3 vs 0.4 NCT00328627
- -2.9 vs 0.4 NCT00328627
- -1.8 vs 0.6 NCT01023581
- -2.5 vs 0.6 NCT01023581
- -2.4 vs 0.2 NCT00328627
- -2.4 vs 0.2 NCT00328627
- -2.7 vs 0.2 NCT00328627
- -1.8 vs 0.4 NCT01023581
- -2.4 vs 0.4 NCT01023581
- -2.0 vs 0.6 NCT01023581
- -2.6 vs 0.6 NCT01023581
- -2.4 vs 0.3 NCT00328627
- -2.3 vs 0.3 NCT00328627
- -2.4 vs 0.3 NCT00328627
- -2.3 vs 0.1 NCT00328627
- -2.3 vs 0.1 NCT00328627
- -2.7 vs 0.1 NCT00328627
- -2.1 vs 0.4 NCT01023581
- -2.5 vs 0.4 NCT01023581
- -1.9 vs 0.5 NCT01023581
- -2.5 vs 0.5 NCT01023581
- -2.0 vs 0.2 NCT00328627
- -2.1 vs 0.2 NCT00328627
- -2.1 vs 0.2 NCT00328627
- -2.4 vs 0.4 NCT00328627
- -2.3 vs 0.4 NCT00328627
- -2.6 vs 0.4 NCT00328627
- -1.9 vs 0.3 NCT01023581
- -2.4 vs 0.3 NCT01023581
- -1.7 vs 0.3 NCT00328627
- -1.7 vs 0.3 NCT00328627
- -1.7 vs 0.3 NCT00328627
- -1.8 vs 0.3 NCT01023581
- -2.0 vs 0.3 NCT01023581
- -1.2 vs 0.1 NCT00328627
- -1.3 vs 0.1 NCT00328627
- -1.3 vs 0.1 NCT00328627
- -1.8 vs 0.7 NCT01023581
- -2.5 vs 0.7 NCT01023581
- -2.3 vs 0.4 NCT00328627
- -2.3 vs 0.4 NCT00328627
- -2.9 vs 0.4 NCT00328627
- -1.1 vs -0.4 NCT01289119
- -1.3 vs -0.4 NCT01289119
- -1.2 vs -0.4 NCT01289119
- -1.0 vs -0.3 NCT01289119
- -1.3 vs -0.3 NCT01289119
- -0.9 vs -0.3 NCT01289119
- -1.2 vs -0.3 NCT01289119
- -1.2 vs -0.3 NCT01289119
- -1.1 vs -0.3 NCT01289119
- -0.7 vs -0.3 NCT01289119
- -1.0 vs -0.3 NCT01289119
- -0.9 vs 0.3 NCT00655863
- -0.9 vs 0.7 NCT00655863
- -1.1 vs -0.2 NCT00655863
- -2.1 vs 0.3 NCT00655863
- -2.1 vs 0.7 NCT00655863
- -2.2 vs -0.2 NCT00655863
- -1.0 vs -0.3 NCT01289119
- -0.6 vs -0.5 NCT00856284
- -1.1 vs -0.3 NCT00432276
- -0.6 vs -0.5 NCT00856284
- -0.6 vs -0.4 NCT00856284
- -1.1 vs -0.3 NCT00432276
- -1 vs -0.3 NCT00432276
- -0.6 vs -0.6 NCT00856284
- -0.6 vs -0.3 NCT00856284
- -1.0 vs -0.1 NCT00432276
- -0.9 vs -0.3 NCT00432276
- -0.6 vs -0.4 NCT00856284
- -0.9 vs -0.0 NCT00432276
- -0.6 vs -0.2 NCT00856284
- -0.9 vs -0.3 NCT00432276
- -0.8 vs -0.3 NCT00432276
- -0.5 vs -0.0 NCT00856284
- -0.9 vs -0.3 NCT00432276
- -0.4 vs 0.1 NCT00856284
- -0.8 vs -0.2 NCT00432276
- -0.3 vs 0.1 NCT00856284
- -0.3 vs 0.3 NCT00856284
- -0.2 vs 0.3 NCT00856284
- -0.2 vs 0.3 NCT00856284
- -0.6 vs -0.5 NCT00856284
- -0.5 vs -0.5 NCT00856284
- -0.5 vs -0.4 NCT00856284
- -0.6 vs -0.6 NCT00856284
- -0.4 vs -0.3 NCT00856284
- -0.6 vs -0.4 NCT00856284
- -0.4 vs -0.2 NCT00856284
- -0.4 vs -0.0 NCT00856284
- -0.3 vs 0.1 NCT00856284
- -0.2 vs 0.1 NCT00856284
- -0.2 vs 0.3 NCT00856284
- -0.1 vs 0.3 NCT00856284
- -0.1 vs 0.3 NCT00856284
- -1.6 vs -2.4 NCT00395512
- -1.6 vs -2.1 NCT00395512
- -1.5 vs -2.3 NCT00395512
- -1.5 vs -1.8 NCT00395512
- -1.6 vs -2.3 NCT00395512
- -0.9 vs -0.8 NCT00395512
- -0.8 vs -0.4 NCT00395512
- -1.4 vs -2.1 NCT00395512
- -1.1 vs -0.3 NCT01263483
- -1.1 vs -0.1 NCT01263483
- -0.9 vs -0.0 NCT01263483
- -0.9 vs -0.2 NCT01263483
- -2.9 vs -2.4 NCT00395512
- -0.9 vs 0.3 NCT01318083
- -1.1 vs -0.1 NCT01318070
- -1.0 vs -0.3 NCT01263483
- -2.8 vs -2.1 NCT00395512
- -2.9 vs -2.3 NCT00395512
- -1.0 vs 0.3 NCT01318083
- -1.2 vs -0.2 NCT01318070
- -1.2 vs -0.1 NCT01263483
- -2.3 vs -1.8 NCT00395512
- -3 vs -2.3 NCT00395512
- -1.3 vs 0.1 NCT01318083
- -1.0 vs -0.2 NCT01318070
- -1.3 vs -0.0 NCT01263483
- -1.9 vs -0.8 NCT00395512
- -1.0 vs 0.0 NCT01318083
- -0.9 vs -0.2 NCT01318070
- -1.0 vs -0.2 NCT01263483
- -1.5 vs -0.4 NCT00395512
- -2.8 vs -2.1 NCT00395512
- -2.7 vs -2.4 NCT00395512
- -1.2 vs 0.3 NCT01318083
- -0.8 vs -0.1 NCT01318070
- -2.7 vs -2.1 NCT00395512
- -2.6 vs -2.3 NCT00395512
- -1.2 vs 0.3 NCT01318083
- -0.9 vs -0.2 NCT01318070
- -2.2 vs -1.8 NCT00395512
- -2.6 vs -2.3 NCT00395512
- -1.2 vs 0.1 NCT01318083
- -0.8 vs -0.2 NCT01318070
- -1.7 vs -0.8 NCT00395512
- -1.0 vs 0.0 NCT01318083
- -0.7 vs -0.2 NCT01318070
- -1.3 vs -0.4 NCT00395512
- -2.7 vs -2.1 NCT00395512
- -1.0 vs 0.3 NCT01263470
- -1.5 vs 0.5 NCT00755846
- -1.0 vs 0.3 NCT01263470
- -1.4 vs 0.3 NCT00755846
- -1.1 vs 0.5 NCT01263470
- -0.8 vs 0.1 NCT01263470
- -0.8 vs 0.3 NCT01263470
- -0.3 vs 0.5 NCT00755846
- -1.0 vs 0.3 NCT01263470
- -0.6 vs 0.3 NCT00755846
- -1.2 vs 0.5 NCT01263470
- -0.9 vs 0.1 NCT01263470
- -1.2 vs 0.5 NCT00755846
- -1.4 vs 0.3 NCT00755846
- -1.3 vs 0.3 NCT01263470
- -0.9 vs 0.5 NCT00755846
- -1.3 vs 0.3 NCT01263470
- -1.0 vs 0.3 NCT00755846
- -1.3 vs 0.5 NCT01263470
- -1.2 vs 0.1 NCT01263470
- -0.5 vs 0.3 NCT01263470
- -0.4 vs 0.5 NCT00755846
- -0.7 vs 0.3 NCT01263470
- -0.4 vs 0.3 NCT00755846
- -0.9 vs 0.5 NCT01263470
- -0.8 vs 0.1 NCT01263470
- -0.9 vs -0.2 NCT01263496
- -0.9 vs -0.4 NCT01263496
- -0.8 vs -0.3 NCT01263496
- -0.8 vs -0.5 NCT01263496
- -0.8 vs -0.4 NCT01263496
- -0.8 vs -0.5 NCT01263496
- -0.9 vs -0.5 NCT01263496
- -0.9 vs -0.8 NCT01263496
- -1.1 vs -0.8 NCT01263496
- -1.3 vs -0.8 NCT01263496
- -1.2 vs -0.7 NCT01263496
- -0.9 vs -0.5 NCT01263496
- -0.8 vs -0.2 NCT01263496
- -0.9 vs -0.4 NCT01263496
- -0.8 vs -0.3 NCT01263496
- -0.7 vs -0.5 NCT01263496
- -0.7 vs -0.4 NCT01263496
- -0.7 vs -0.5 NCT01263496
- -0.8 vs -0.5 NCT01263496
- -0.8 vs -0.8 NCT01263496
- -1.0 vs -0.8 NCT01263496
- -1.1 vs -0.8 NCT01263496
- -1.1 vs -0.7 NCT01263496
- -0.9 vs -0.5 NCT01263496
- -1.3 vs -0.2 NCT01263496
- -1.0 vs -0.4 NCT01263496
- -1.1 vs -0.3 NCT01263496
- -1.1 vs -0.5 NCT01263496
- -1.1 vs -0.4 NCT01263496
- -1.1 vs -0.5 NCT01263496
- -1.2 vs -0.5 NCT01263496
- -1.3 vs -0.8 NCT01263496
- -1.4 vs -0.8 NCT01263496
- -1.4 vs -0.8 NCT01263496
- -1.4 vs -0.7 NCT01263496
- -1.5 vs -0.5 NCT01263496
- -0.7 vs -0.2 NCT01263496
- -0.6 vs -0.4 NCT01263496
- -0.6 vs -0.3 NCT01263496
- -0.6 vs -0.5 NCT01263496
- -0.5 vs -0.4 NCT01263496
- -0.8 vs -0.5 NCT01263496
- -0.6 vs -0.5 NCT01263496
- -0.8 vs -0.8 NCT01263496
- -0.9 vs -0.8 NCT01263496
- -0.9 vs -0.8 NCT01263496
- -0.8 vs -0.7 NCT01263496
- -0.6 vs -0.5 NCT01263496
- Trelagliptin
- -0.9 vs -0.0−0.9 vs placeboNCT02512068
3 other results
- -0.7 vs -0.2 NCT02512068
- -0.6 vs -0.1 NCT02512068
- -0.7 vs 0.1 NCT02512068
3-point MACE (% with event)
- Alogliptin
- 11.3% vs 11.8%−0.5 vs placeboNCT00968708
- Trelagliptin
- —Not posted · NCT03940183
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Alogliptin: 4 of 4 rows · Trelagliptin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Alogliptin | Trelagliptin |
|---|---|---|
| Dropout rate | 40.3%25 mg QDa NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 69 more results36.6%12.5 mg QD NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 18.3%25 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 21.1%12.5 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 20%25 mg NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3 11% NCT00968708 · Phase 3 14.9% NCT01456130 · Phase 3 · registry result, not featured evidence 44.3%25 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 46.4%12.5 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 9.8%Alogliptin Monotherapy NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy 6.1%Metformin + Alogliptin Add-on Ther NCT01289119 · Phase 3 · registry result, not featured evidence · combination 6.6%Pioglitazone + Alogliptin Add-on T NCT01289119 · Phase 3 · registry result, not featured evidence · combination 36.3%25 mg NCT00306384 · Phase 3 · registry result, not featured evidence 38.8%12.5 mg NCT00306384 · Phase 3 · registry result, not featured evidence 20.5%25 mg QD NCT01023581 · Phase 3 · registry result, not featured evidence 37.2%12.5 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence 17.5%alogliptin 12.5 mg BID + metformin 1000 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 17.1%alogliptin 12.5 mg BID + metformin 500 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 0%25 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence 4.5%25 mg QD + 30 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence · combination 30%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin NCT00432276 · Phase 3 · registry result, not featured evidence · combination 21.7%25 mg NCT00328627 · Phase 3 · registry result, not featured evidence 24.2%12.5 mg NCT00328627 · Phase 3 · registry result, not featured evidence 15.4%25 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 13.1%25 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 12.3%25 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 11.5%12.5 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 10.8%12.5 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 13.8%12.5 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 23.2%25 mg NCT00395512 · Phase 3 · registry result, not featured evidence 17.1%25 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 23.2%12.5 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 19.6%25 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 22.3%12.5 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 21.4%25 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 17.4%12.5 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 25.3%25 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence 24.6%12.5 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence —25 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —25 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —12.5 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —12.5 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 1.9%25 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 5.7%12.5 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination —Alogliptin 25 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination —Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination 1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 1.8%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 2.6%12.5 mg QD NCT01263483 · Phase 2/3 · registry result, not featured evidence 6.3%25 mg QD + 0.2 mg TID NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination —25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 3.8%25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 4.8%12.5 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 3.8%50 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 6.3%6.25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 28.9%25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 27.3%12.5 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 31.1%100 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 38.6%50 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 38.6%6.25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 12.5%12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%Roflumilast + Alogliptin NCT01664624 · Phase 1 · registry result, not featured evidence · combination 0%Roflumilast Alone NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy | 21.8%25 mgb NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 1 more result0% NCT03014479 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | 4.7%25 mg QDa NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 69 more results0.8%12.5 mg QD NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.5%25 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2.3%12.5 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0%25 mg NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3 5.6% NCT00968708 · Phase 3 6% NCT01456130 · Phase 3 · registry result, not featured evidence 8.4%25 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 6.8%12.5 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 1.1%Alogliptin Monotherapy NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy 2%Metformin + Alogliptin Add-on Ther NCT01289119 · Phase 3 · registry result, not featured evidence · combination 0%Pioglitazone + Alogliptin Add-on T NCT01289119 · Phase 3 · registry result, not featured evidence · combination 6.2%25 mg NCT00306384 · Phase 3 · registry result, not featured evidence 7.4%12.5 mg NCT00306384 · Phase 3 · registry result, not featured evidence 3.6%25 mg QD NCT01023581 · Phase 3 · registry result, not featured evidence 6.2%12.5 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence 9.6%alogliptin 12.5 mg BID + metformin 1000 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 4.5%alogliptin 12.5 mg BID + metformin 500 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination —25 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence —25 mg QD + 30 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence · combination 3.2%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin NCT00432276 · Phase 3 · registry result, not featured evidence · combination 1.6%25 mg NCT00328627 · Phase 3 · registry result, not featured evidence 0.8%12.5 mg NCT00328627 · Phase 3 · registry result, not featured evidence 1.5%25 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 0%25 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 3.1%25 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 0.8%12.5 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.5%12.5 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 3.8%12.5 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.8%25 mg NCT00395512 · Phase 3 · registry result, not featured evidence 3.7%25 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 3.7%12.5 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 3%25 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 4.1%12.5 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 2.9%25 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 3.3%12.5 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 2%25 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence 3%12.5 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence —25 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —25 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —12.5 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —12.5 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 1%25 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 3.8%12.5 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination —Alogliptin 25 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination —Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination 0.9%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0%12.5 mg QD NCT01263483 · Phase 2/3 · registry result, not featured evidence 3.8%25 mg QD + 0.2 mg TID NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination —25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 1.3%25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 1.2%12.5 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.5%50 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.5%6.25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.2%25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%12.5 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 4.4%100 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 6.8%50 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%6.25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence —25 mg NCT00957268 · Phase 1 · registry result, not featured evidence —25 mg NCT00957268 · Phase 1 · registry result, not featured evidence —25 mg NCT00957268 · Phase 1 · registry result, not featured evidence —12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence —12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%Roflumilast + Alogliptin NCT01664624 · Phase 1 · registry result, not featured evidence · combination 0%Roflumilast Alone NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy | 14.5%25 mgb NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 1 more result0% NCT03014479 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 5.4%25 mg QDa NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 69 more results6.1%12.5 mg QD NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.8%25 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 3.8%12.5 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2.7%25 mg NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3 33.6% NCT00968708 · Phase 3 9% NCT01456130 · Phase 3 · registry result, not featured evidence 11%25 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 9.9%12.5 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 2.2%Alogliptin Monotherapy NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy 0%Metformin + Alogliptin Add-on Ther NCT01289119 · Phase 3 · registry result, not featured evidence · combination 1.6%Pioglitazone + Alogliptin Add-on T NCT01289119 · Phase 3 · registry result, not featured evidence · combination 16.3%25 mg NCT00306384 · Phase 3 · registry result, not featured evidence 16.7%12.5 mg NCT00306384 · Phase 3 · registry result, not featured evidence 0.9%25 mg QD NCT01023581 · Phase 3 · registry result, not featured evidence 3.6%12.5 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence 1.8%alogliptin 12.5 mg BID + metformin 1000 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 1.9%alogliptin 12.5 mg BID + metformin 500 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 8%25 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence 13.6%25 mg QD + 30 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence · combination 5%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin NCT00432276 · Phase 3 · registry result, not featured evidence · combination 4.7%25 mg NCT00328627 · Phase 3 · registry result, not featured evidence 3.9%12.5 mg NCT00328627 · Phase 3 · registry result, not featured evidence 0.8%25 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 4.6%25 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 3.8%25 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.5%12.5 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 2.3%12.5 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.5%12.5 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 0.6%25 mg NCT00395512 · Phase 3 · registry result, not featured evidence 4.9%25 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 0.6%12.5 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 6.5%25 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 2.5%12.5 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 3.9%25 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 2.8%12.5 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 5.6%25 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence 5.4%12.5 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence 2%25 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 3.4%25 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 10.7%12.5 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 4.9%12.5 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 1%25 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 2.9%12.5 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 6.7%Alogliptin 25 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination 5.6%Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination 1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0%12.5 mg QD NCT01263483 · Phase 2/3 · registry result, not featured evidence 1.3%25 mg QD + 0.2 mg TID NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination 8.2%25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 7.9%12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 5.2%50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 2.1%6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 1.3%25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.4%12.5 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.5%50 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.5%6.25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.2%25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%12.5 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%100 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%50 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 2.4%6.25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 10%Roflumilast + Alogliptin NCT01664624 · Phase 1 · registry result, not featured evidence · combination 0%Roflumilast Alone NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy | 41.8%25 mgb NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 1 more result1.8% NCT03014479 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | 25 mg QDa urinary tract infection 7% (placebo 7.8%) diarrhoea 6.2% (placebo 5.4%) nasopharyngitis 6.2% (placebo 4.7%) NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 69 more results12.5 mg QD arthralgia 6.9% (placebo 2.3%) urinary tract infection 6.1% (placebo 7.8%) headache 5.3% (placebo 4.7%) NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 25 mg QD nasopharyngitis 7.6% (placebo 7.8%) headache 6.8% (placebo 4.7%) upper respiratory tract infection 4.5% (placebo 9.4%) NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 12.5 mg QD nasopharyngitis 9% (placebo 7.8%) headache 7.5% (placebo 4.7%) back pain 5.3% (placebo 4.7%) NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 25 mg headache 18.7% (placebo 10.5%) hyperglycaemia 12% (placebo 11.8%) diarrhoea 9.3% (placebo 9.2%) NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3 renal impairment 7.5% (placebo 6.5%) hypertension 7.1% (placebo 7.4%) hypoglycaemia 6.2% (placebo 5.9%) NCT00968708 · Phase 3 nasopharyngitis 35.8% upper respiratory tract inflammation 11.9% arthralgia 7.5% NCT01456130 · Phase 3 · registry result, not featured evidence 25 mg upper respiratory tract infection 10.3% hypertension 7.6% nasopharyngitis 7.6% NCT00856284 · Phase 3 · registry result, not featured evidence · combination 12.5 mg upper respiratory tract infection 9.6% nasopharyngitis 8.9% diarrhoea 6.9% NCT00856284 · Phase 3 · registry result, not featured evidence · combination hyperlipidaemia 6.5% (placebo 1.1%) upper respiratory tract infection 5.4% (placebo 3.3%) blood triglycerides increased 2.2% (placebo 1.1%) NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy upper respiratory tract infection 3% (placebo 3.3%) blood triglycerides increased 2% (placebo 1.1%) urinary tract infection 2% (placebo 6.5%) NCT01289119 · Phase 3 · registry result, not featured evidence · combination hyperlipidaemia 21.3% (placebo 1.1%) urinary tract infection 6.6% (placebo 6.5%) upper respiratory tract infection 3.3% (placebo 3.3%) NCT01289119 · Phase 3 · registry result, not featured evidence · combination 25 mg hypertension 14.5% urinary tract infection 11.7% nasopharyngitis 11.6% NCT00306384 · Phase 3 · registry result, not featured evidence 12.5 mg hypertension 14.8% upper respiratory tract infection 11.6% urinary tract infection 11.1% NCT00306384 · Phase 3 · registry result, not featured evidence 25 mg QD hyperglycaemia 17% (placebo 26.4%) nasopharyngitis 6.3% (placebo 1.9%) headache 5.4% (placebo 2.8%) NCT01023581 · Phase 3 · registry result, not featured evidence 12.5 mg BID hyperglycaemia 11.8% (placebo 26.4%) headache 4.5% (placebo 2.8%) creatinine renal clearance decreased 3.6% (placebo 3.8%) NCT01023581 · Phase 3 · registry result, not featured evidence alogliptin 12.5 mg BID + metformin 1000 mg BID creatinine renal clearance decreased 7.9% (placebo 3.8%) diarrhoea 7% (placebo 2.8%) dyspepsia 7% (placebo 2.8%) NCT01023581 · Phase 3 · registry result, not featured evidence · combination alogliptin 12.5 mg BID + metformin 500 mg BID hyperglycaemia 7.5% (placebo 26.4%) upper respiratory tract infection 7.5% (placebo 2.8%) headache 6.6% (placebo 2.8%) NCT01023581 · Phase 3 · registry result, not featured evidence · combination 25 mg QD nasopharyngitis 20% (placebo 4.2%) anaemia 12% (placebo 4.2%) constipation 8% (placebo 4.2%) NCT00655863 · Phase 3 · registry result, not featured evidence 25 mg QD + 30 mg QD hypoglycaemia 13.6% (placebo 0%) nasopharyngitis 13.6% (placebo 4.2%) constipation 9.1% (placebo 4.2%) NCT00655863 · Phase 3 · registry result, not featured evidence · combination Alogliptin 25 mg; Pioglitazone 30 mg; Metformin upper respiratory tract infection 7.2% nasopharyngitis 6.9% hypertension 5.9% NCT00432276 · Phase 3 · registry result, not featured evidence · combination 25 mg headache 7% (placebo 4.7%) upper respiratory tract infection 6.2% (placebo 3.9%) abdominal pain upper 5.4% (placebo 1.6%) NCT00328627 · Phase 3 · registry result, not featured evidence 12.5 mg hypertriglyceridaemia 5.5% (placebo 2.3%) hypertension 4.7% (placebo 3.1%) urinary tract infection 4.7% (placebo 4.7%) NCT00328627 · Phase 3 · registry result, not featured evidence 25 mg + 15 mg influenza 6.2% (placebo 2.3%) nasopharyngitis 6.2% (placebo 3.9%) oedema peripheral 5.4% (placebo 1.6%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 25 mg + 30 mg nasopharyngitis 6.9% (placebo 3.9%) back pain 6.2% (placebo 3.9%) influenza 6.2% (placebo 2.3%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 25 mg + 45 mg diarrhoea 5.4% (placebo 8.5%) headache 4.6% (placebo 4.7%) oedema peripheral 4.6% (placebo 1.6%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 12.5 mg + 15 mg hypertension 6.9% (placebo 3.1%) nasopharyngitis 6.2% (placebo 3.9%) dizziness 5.4% (placebo 3.1%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 12.5 mg + 30 mg dizziness 3.8% (placebo 3.1%) nasopharyngitis 3.8% (placebo 3.9%) upper respiratory tract infection 3.8% (placebo 3.9%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 12.5 mg + 45 mg back pain 9.2% (placebo 3.9%) dizziness 4.6% (placebo 3.1%) headache 4.6% (placebo 4.7%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 25 mg headache 6.7% urinary tract infection 3% oedema peripheral 1.2% NCT00395512 · Phase 3 · registry result, not featured evidence 25 mg + 30 mg headache 12.2% back pain 6.1% urinary tract infection 5.5% NCT00395512 · Phase 3 · registry result, not featured evidence · combination 12.5 mg + 30 mg headache 8.6% urinary tract infection 3.7% back pain 1.8% NCT00395512 · Phase 3 · registry result, not featured evidence · combination 25 mg QD nasopharyngitis 7% (placebo 6.2%) influenza 5.5% (placebo 4.1%) oedema peripheral 5.5% (placebo 7.2%) NCT00286494 · Phase 3 · registry result, not featured evidence 12.5 mg QD oedema peripheral 6.1% (placebo 7.2%) upper respiratory tract infection 5.6% (placebo 5.2%) nausea 4.5% (placebo 2.1%) NCT00286494 · Phase 3 · registry result, not featured evidence 25 mg QD diarrhoea 3.4% (placebo 5.8%) nasopharyngitis 3.4% (placebo 5.8%) bronchitis 2.9% (placebo 1.9%) NCT00286442 · Phase 3 · registry result, not featured evidence 12.5 mg QD urinary tract infection 6.6% (placebo 3.8%) nasopharyngitis 5.6% (placebo 5.8%) upper respiratory tract infection 4.7% (placebo 6.7%) NCT00286442 · Phase 3 · registry result, not featured evidence 25 mg QD headache 5.6% (placebo 3%) hypertension 5.6% (placebo 2%) urinary tract infection 5.1% (placebo 3%) NCT00286468 · Phase 3 · registry result, not featured evidence 12.5 mg QD urinary tract infection 4.4% (placebo 3%) diarrhoea 3.9% (placebo 0%) hypertriglyceridaemia 3.9% (placebo 2%) NCT00286468 · Phase 3 · registry result, not featured evidence 25 mg QD and 1-6 mg QD or BID nasopharyngitis 37.5% upper respiratory tract inflammation 10.5% fall 7.9% NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 25 mg QD and 500 mg BID or 750 mg TID nasopharyngitis 36.6% diabetic retinopathy 6.9% constipation 5.5% NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 12.5 mg QD and 1-6 mg QD or BID nasopharyngitis 30.7% upper respiratory tract inflammation 6.7% back pain 5.3% NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 12.5 mg QD and 500 mg BID or 750 mg TID nasopharyngitis 31% back pain 6.3% headache 6.3% NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 25 mg QD nasopharyngitis 19.2% upper respiratory tract inflammation 11.5% back pain 3.8% NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 12.5 mg QD nasopharyngitis 19% gastroenteritis 3.8% upper respiratory tract inflammation 1.9% NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination Alogliptin 25 mg QD and Voglibose 0.2 mg TID nasopharyngitis 28.6% back pain 5.7% arthralgia 4.8% NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID nasopharyngitis 35.2% upper respiratory tract inflammation 11.1% back pain 7.4% NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD nasopharyngitis 11.5% blood creatine phosphokinase increased 3.5% dental caries 0% NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD nasopharyngitis 4.5% blood creatine phosphokinase increased 0% dental caries 0% NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 12.5 mg QD nasopharyngitis 22.4% eczema 1.3% NCT01263483 · Phase 2/3 · registry result, not featured evidence 25 mg QD + 0.2 mg TID nasopharyngitis 16.5% eczema 0% NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination 25 mg QD nasopharyngitis 33% headache 7.2% upper respiratory tract inflammation 7.2% NCT01263496 · Phase 2 · registry result, not featured evidence 12.5 mg QD nasopharyngitis 28.7% bronchitis 5.9% back pain 5% NCT01263496 · Phase 2 · registry result, not featured evidence 50 mg QD nasopharyngitis 35.1% blood creatine phosphokinase increased 8.2% back pain 7.2% NCT01263496 · Phase 2 · registry result, not featured evidence 6.25 mg QD nasopharyngitis 30.2% upper respiratory tract inflammation 8.3% back pain 7.3% NCT01263496 · Phase 2 · registry result, not featured evidence 25 mg QD nasopharyngitis 12.5% (placebo 6.7%) headache 6.3% (placebo 5.3%) abdominal distension 3.8% (placebo 0%) NCT01263470 · Phase 2 · registry result, not featured evidence 12.5 mg QD nasopharyngitis 8.3% (placebo 6.7%) flatulence 4.8% (placebo 2.7%) urticaria 3.6% (placebo 0%) NCT01263470 · Phase 2 · registry result, not featured evidence 50 mg QD nasopharyngitis 10.1% (placebo 6.7%) blood creatine phosphokinase increased 5.1% (placebo 2.7%) abdominal distension 2.5% (placebo 0%) NCT01263470 · Phase 2 · registry result, not featured evidence 6.25 mg QD nasopharyngitis 6.3% (placebo 6.7%) bronchitis 3.8% (placebo 1.3%) flatulence 2.5% (placebo 2.7%) NCT01263470 · Phase 2 · registry result, not featured evidence 25 mg QD headache 8.9% (placebo 7.3%) abdominal pain upper 6.7% (placebo 0%) dizziness 6.7% (placebo 0%) NCT00755846 · Phase 2 · registry result, not featured evidence 12.5 mg QD rash 9.1% (placebo 2.4%) abdominal pain 4.5% (placebo 0%) arthralgia 4.5% (placebo 0%) NCT00755846 · Phase 2 · registry result, not featured evidence 100 mg QD nausea 11.4% (placebo 0%) headache 9.1% (placebo 7.3%) urinary tract infection 9.1% (placebo 9.8%) NCT00755846 · Phase 2 · registry result, not featured evidence 50 mg QD diarrhoea 7% (placebo 7.3%) headache 7% (placebo 7.3%) urinary tract infection 7% (placebo 9.8%) NCT00755846 · Phase 2 · registry result, not featured evidence 6.25 mg QD urinary tract infection 7.1% (placebo 9.8%) abdominal pain upper 4.8% (placebo 0%) dizziness 4.8% (placebo 0%) NCT00755846 · Phase 2 · registry result, not featured evidence 25 mg rash papular 25% abdominal pain 0% blood creatine phosphokinase increased 0% NCT00957268 · Phase 1 · registry result, not featured evidence 25 mg blood creatine phosphokinase increased 14.3% haematocrit decreased 14.3% haemoglobin decreased 14.3% NCT00957268 · Phase 1 · registry result, not featured evidence 25 mg headache 18.2% fatigue 9.1% nausea 9.1% NCT00957268 · Phase 1 · registry result, not featured evidence 12.5 mg diarrhoea 20% neutrophil count decreased 20% pyrexia 20% NCT00957268 · Phase 1 · registry result, not featured evidence 12.5 mg abdominal pain 25% gastritis 12.5% headache 12.5% NCT00957268 · Phase 1 · registry result, not featured evidence headache 30% nausea 20% constipation 10% NCT01664624 · Phase 1 · registry result, not featured evidence · combination nausea 50% diarrhoea 40% vomiting 30% NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy | 25 mgb nasopharyngitis 43.6% (placebo 33.3%) fall 21.8% (placebo 10.4%) hypoglycaemia 21.8% (placebo 14.6%) NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 1 more resultviral upper respiratory tract infection 3.6% NCT03014479 · Phase 4 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 65 of these studies.
- bPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Alogliptin
show 5 more results
show 7 more results
show 7 more results
show 7 more results
show 9 more results
show 9 more results
show 9 more results
show 9 more results
show 111 more results
show 78 more results
+ 61 further endpoints in the CSV export.
Trelagliptin
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alogliptin's landscape · Trelagliptin's landscape